stockportfolio.pro
PTC Therapeutics, Inc. (PTCT)
Healthcare · Biotechnology · NasdaqGS
PTC Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.70M | $194.39M | $264.73M | $306.98M | $380.77M | $538.59M | $698.80M | $937.82M | $806.78M | $1.73B |
| Gross profit | — | $189.81M | $252.06M | $294.85M | — | — | — | — | — | — |
| Net income | $-142.11M | $-79.00M | $-128.08M | $-251.58M | $-438.16M | $-523.90M | $-559.02M | $-626.60M | $-363.30M | $682.64M |
| Net margin | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
Source: PTC Therapeutics, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of PTC Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PTCT in your portfolio →
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
PTC Therapeutics, Inc. — frequently asked questions
What is PTC Therapeutics, Inc.'s revenue?
PTC Therapeutics, Inc. (PTCT) reported revenue of $1.73B for fiscal year 2025, up 114.5% from the prior year, according to its SEC filings.
Is PTC Therapeutics, Inc. profitable?
Yes. PTCT earned net income of $682.64M in fiscal 2025, a net margin of 39.4%.
What is PTCT's P/E ratio?
PTC Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is PTC Therapeutics, Inc. growing?
PTCT's revenue grew at roughly 35.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from PTC Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.